Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
ÖGGH · 2025 · Austria
Source and licence
- Authors
- Mattias Mandorfer, Georg Semmler, Elmar Aigner et al.
- Title
- Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
- Journal
- Wiener Klinische Wochenschrift, 2025
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC12534228
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
This joint consensus document of the Austrian Societies of Gastroenterology and Hepatology (ÖGGH), Diabetology (ÖDG), and Obesity (ÖAG) is intended to provide practical guidance for the management of persons with metabolic dysfunction-associated steatotic liver disease (MASLD), including persons with combined metabolic dysfunction and alcohol-related steatotic liver disease (MetALD).
Contents of the original publication
The section headings of the original.
- Introduction
- Definitions
- Prevalence
- Risk factors for disease progression
- Alcohol consumption and assessment
- Case finding
- Fibrosis assessment and risk stratification
- Risk stratification regarding CSPH
- Steatosis assessment
- Liver biopsy
- General management
- Nonpharmacological therapy
- General management in cACLD/cirrhosis
- Pharmacological treatment
- Pharmacological treatment in cACLD/cirrhosis
- Metabolic/bariatric surgery
- Natural history and general management
- Monitoring of comorbidities
- Monitoring of fibrosis
- Monitoring intervals
- Monitoring steatosis
- HCC surveillance
- Ethical standards
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint